The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations

Tuesday, September 06, 2011

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations08:30 EDT Tuesday, September 06, 2011NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following September 2011 investor conferences:Stifel Nicolaus Healthcare Conference (Boston, MA)Wednesday, September 7, 201110:55am ETRodman & Renshaw Annual Global Investment Conference (New York, NY)Monday, September 12, 201110:50am ETUBS Global Life Sciences Conference (New York, NY)Tuesday, September 20, 201111:00am ETJMP Securities Sixth Annual Healthcare Conference (New York, NY)Tuesday, September 27, 201110:30am ETEach of the presentations will be live audio webcast, and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. Archived versions of each webcast will be available following the conclusion of the live presentation.ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other signal transduction pathways, including the JNK pathway, believed to be associated with cell death, growth, differentiation and survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.comSOURCE Keryx Biopharmaceuticals, Inc.